Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 18 h ago

Zentalis Pharmaceuticals, Inc.: 5AM Opportunities II (GP), LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

5AM Opportunities II (GP), LLC amended its Schedule 13G stake filing for Zentalis Pharmaceuticals, Inc., disclosing the change in a filing with the SEC under accession number 0001873515-26-000003. The amendment updates the investment firm's reported ownership position in the clinical-stage oncology company. Schedule 13G filings are used by investors holding passive stakes, and amendments typically signal a change in the size of that position. The filing did not disclose the specific number of shares or percentage held in the summary. Investors will watch for further 13G or 13D filings to gauge whether 5AM Opportunities is building or trimming its position in Zentalis.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

5AM Opportunities II (GP), LLC, Zentalis Pharmaceuticals, Inc.